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Abstract
Identifying early-onset schizophrenia spectrum disorders (SSD) at a very
early stage remains challenging. To assess the diagnostic predictive value
of multiple types of data at the emergence of early-onset first-episode
psychosis (FEP), various support vector machine (SVM) classifiers were
developed. The data were from a 2-year, prospective, longitudinal study
of 81 patients (age 9–17 years) with early-onset FEP and a stable
diagnosis during follow-up and 42 age- and sex-matched healthy controls
(HC). The input was different combinations of baseline clinical,
neuropsychological, magnetic resonance imaging brain volumetric and
biochemical data, and the output was the diagnosis at follow-up (SSD vs.
non-SSD, SSD vs. HC, and non-SSD vs. HC). Enhanced recursive feature
elimination was performed for the SSD vs. non-SSD classifier to select
and rank the input variables with the highest predictive value for a
diagnostic outcome of SSD. After validation with a test set and
considering all baseline variables together, the SSD vs. non-SSD, SSD vs.
HC and non-SSD vs. HC classifiers achieved an accuracy of 0.81, 0.99
and 0.99, respectively. Regarding the SSD vs. non-SSD classifier, a
combination of baseline clinical variables (severity of negative,
disorganized symptoms and hallucinations or poor insight) and
neuropsychological variables (impaired attention, motor coordination, and
global cognition) showed the highest predictive value for a diagnostic
outcome of SSD. Neuroimaging and biochemical variables at baseline did
not add to the predictive value. Thus, comprehensive clinical/cognitive
assessment remains the most reliable approach for differential diagnosis
during early-onset FEP. SVMs may constitute promising multivariate tools
in the search for predictors of diagnostic outcome in FEP.
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Support vector machines
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Introduction
Psychotic disorders are among the leading causes of disease burden in
adolescents and young people [ 1 , 2 ]. The rapid distinction between
schizophrenia spectrum disorders (SSD) and other psychotic disorders such
as bipolar disorder is thus an important challenge for child and adolescent
psychiatrists, since it may enable early optimization of treatment and
accurate use of prognostic statements [ 3 ]. However, this could prove
extremely difficult in patients with first episodes of psychosis (FEP),
particularly in early-onset cases, for a number of reasons. First, although the
clinical approach to psychosis is evolving towards a dimensional model [ 4 ],
symptom-based categorical classification of patients is still the basis for
diagnosis during a FEP [ 5 , 6 ]; however, differential diagnosis might be
hampered by the lack of specificity of symptoms at this stage (e.g. positive
psychotic symptoms may be shared by SSD, bipolar disorder and other
psychotic disorders). Second, categorical classifications require a temporal
criterion for a diagnosis of SSD or other psychotic disorders [ 5 , 6 ].
Therefore, the initial diagnosis can shift during follow-up [ 7 – 9 ]. For these
reasons, the stability of diagnosis in FEP patients is very low (around 60 %)
[ 7 – 10 ]. Third, SSD and other disorders such as bipolar disorder with
psychotic symptoms share not only symptomatic features but also many
cognitive and biological features and risk factors [ 11 ].
To date, numerous clinical and biological variables have been studied during
the FEP with regard to their diagnostic predictive value for SSD. For
example, clinical variables such as history of obstetric complications [ 12 ],
the presence of negative symptoms [ 9 , 13 ], or poor general functioning [ 8 ,
14 ] at onset of the illness are good clinical predictors of an SSD diagnostic
outcome both in adult and adolescent samples. Among neuropsychological
variables, executive function impairments in FEP patients seem to be good
predictors of schizophrenia both in adult [ 15 ] and adolescent samples [ 16 ].
Regarding neuroimaging variables, prefrontal, cingulate, insular and
cerebellar gray matter (GM) volume reductions have been associated with
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conversion to psychosis in individuals at high risk of psychosis [ 17 ], and
GM deficits in the prefrontal cortex, insula, amygdala or hippocampus have
been associated with a diagnosis of schizophrenia (but not bipolar disorder)
both in FEP and chronic patients [ 18 – 20 ]. Lastly, low antioxidant status
during early-onset FEP has been described both in patients with
schizophrenia and bipolar disorder, while reduced plasma levels of
glutathione were only found in those patients with schizophrenia [ 21 ].
Despite the increasing body of literature, the reported predictive weight of
the above-mentioned variables has been too small to have diagnostic value
for SSD [ 22 , 23 ]. The main caveats of predictive studies to date include (1)
the use of relatively small samples of patients that do not allow for
subdivision of patients into diagnostic groups within psychosis, (2) the
inclusion of chronic (instead of first-episode) patients, (3) the use of
traditional multivariate statistical approaches such as linear discriminant
analysis (LDA) or logistic regression (LR), and (4) the fact that most studies
have focused on a specific measurement or a specific source of
measurements (e.g. clinical, neuropsychological, neuroimaging or
biochemical data alone), and have relied on a limited number of variables
(e.g. total scores or subscores of a particular clinical or neuropsychological
scale). Other fields of medicine have demonstrated that clinical prediction,
especially in complex disorders, often requires a combination of multiple
measurements from different sources [ 24 ]. To this end, prediction
methodologies based on high-dimensional multivariate statistical approaches
and including a combination of multiple clinical and biological data seem to
be needed and could potentially improve prediction accuracy [ 25 ]. One of
these methods is support vector machines (SVMs), a multivariate pattern
recognition approach that emerges from the field of machine learning [ 26 ,
27 ], which enables the following: (1) classification of two diagnostic groups
by considering high-dimensional qualitative and quantitative variable
information from each subject, from different sources and at the same time,
and (2) description of the combination of variables with the highest
predictive value for each diagnostic group (i.e. those that contribute the most
to the discriminating pattern from each diagnostic class). Compared to other
multivariate pattern analysis techniques such as LR or LDA, SVMs require
fewer variables to achieve better prediction estimates, perform better when
high-correlation structures are observed in the data, do not need multiple
comparison correction (e.g. false discovery rate [FDR] or Bonferroni
correction), and do not impose any a priori assumptions on single variable
8/8/2014 e.Proofing
http://eproofing.springer.com/journals/printpage.php?token=me2DpncaDLIav2ZIXkLp6U4sZ0JnpjsMdeepZPkT_8U 6/32
relevance or data distribution except that they be “independent and
identically distributed” (iid) [ 28 ].
The aim of this study was to develop an SVM model to assess the
differential predictive values for a diagnostic outcome of SSD in a large set
of clinical, neuropsychological, neuroimaging and biochemical data at the
emergence of an early-onset FEP. Based on previous literature, we proposed
the following hypotheses: (1) a combination of clinical variables (negative
symptoms, premorbid functioning), neuropsychological variables (executive
function), and neuroimaging variables (frontal volume) at baseline (i.e.
during the FEP) will help us predict a diagnostic outcome of SSD, and (2)
the SVM model that includes this combination of variables at baseline will
classify with high accuracy FEP patients who will eventually be diagnosed
with SSD.
Subjects and methods
Procedure
The child and adolescent first-episode psychosis study (CAFEPS) is a 2-
year, multicenter, prospective, longitudinal study of 110 patients with an
early-onset FEP and 98 age- and sex-matched healthy controls who were
recruited from six different sites in Spain. The inclusion criteria for patients
were age between 7 and 17 years at the initial evaluation and a first
psychotic episode following DSM-IV criteria [ 5 ] (the presence of positive
symptoms such as delusions and/or hallucinations) of less than 6 months’
duration. The exclusion criteria were the presence of a concomitant Axis I
disorder, mental retardation according to DSM-IV criteria [ 5 ] (i.e. not only
an intelligence quotient below 70, but also impaired functioning prior to onset
of the disorder), pervasive developmental disorders, neurological diseases,
history of head trauma with loss of consciousness, and pregnancy. The
inclusion criteria for controls were similar age as patients, residence in the
same geographical areas, and the absence of psychiatric or neurological
disorders, head trauma, mental retardation, and pregnancy. Sample
recruitment and methodology have been described elsewhere [ 29 ].
Diagnosis was made according to DSM-IV criteria [ 5 ] using the Spanish
version of the Kiddie-SADS present and lifetime version (K-SADS-PL)
instrument [ 30 ] at baseline and at years 1 and 2 by experienced child
psychiatrists with specific training for the interview. For the purposes of this
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study, patients were categorized as ‘SSD’ (diagnosed with schizophrenia,
schizoaffective disorder, or schizophreniform disorder during follow-up) or
‘non-SSD’ (diagnosed with bipolar disorder, major depressive disorder with
psychotic symptoms, brief psychotic disorder, or psychotic disorder not
otherwise specified during follow-up). Other authors [ 9 , 14 ] have grouped
schizophrenia, schizoaffective disorder, and schizophreniform disorder
together, as they all have similar schizophrenia-like psychotic features.
Clinical and neuropsychological assessments, a magnetic resonance imaging
(MRI) scan and blood samples for oxidative stress determinations were
obtained at baseline at all the sites. A complete description of the clinical,
neuropsychological, neuroimaging and biochemical assessment procedures is
provided as Online Resource 1.
Selected sample and dataset construction
Subject selection
Since the outcome variable of this study was a diagnostic outcome, only
those CAFEPS patients with a stable K-SADS-based diagnosis at follow-up
[i.e. obtained at year 1 (N = 18) or year 2 (N = 63)] were included in the
analysis. This was done to avoid the problem of diagnostic instability. In
fact, 15 patients (18.5 % of patients included in this study) had a diagnostic
category at baseline that shifted during follow-up (Fig. 1 ).
Fig. 1
Diagnostic stability of first episodes of early-onset psychosis over the follow-
up period. For all subjects, a diagnosis was established at baseline and at
follow-up according to DSM-IV criteria [5 ] using the Kiddie-schedule for
affective disorders and schizophrenia, present and lifetime version (K-SADS-
PL) diagnostic scale [30 ]. Fifteen patients (14 non-SSD and 1 SSD) had a
diagnostic category at baseline that shifted during follow-up. *Follow-up refers
to year 1 follow-up diagnostic assessment (available for 18 patients) or year 2
follow-up diagnostic assessment (available for 63 patients and 42 controls).
SSD schizophrenia spectrum disorders (including schizophrenia,
schizophreniform disorder, and schizoaffective disorder), non-SSD non-
schizophrenia spectrum disorders (including bipolar disorder, major depressive
disorder with psychotic symptoms, brief psychotic disorder, and psychotic
disorder not otherwise specified)
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Additionally, to include all the available information in the dataset on a
subject-by-subject basis, only those subjects with complete or almost
complete (>95 %) data for the four sets of variables (clinical,
neuropsychological, neuroimaging and biochemical variables) were included
in the analysis.
Out of the original CAFEPS sample of 110 patients, 10 were excluded
because they did not have a stable K-SADS-based diagnosis at follow-up
(since they were lost to follow-up before the visit at year 1), 18 were
excluded because they did not have baseline imaging data, and 1 was
excluded because of unavailable neuropsychological assessment at baseline.
The final sample comprised 81 FEP patients (70 % males) with a mean age
of 15.38 ± 1.90 years (range 9–17 years). Of these, 49 patients were
categorized as SSD [diagnosed with schizophrenia (n = 39), schizoaffective
disorder (n = 7), or schizophreniform disorder (n = 3) during follow-up], and
32 as non-SSD [diagnosed with bipolar disorder (n = 20), major depressive
disorder with psychotic symptoms (n = 5), brief psychotic disorder (n = 2),
or psychotic disorder not otherwise specified (n = 5) during follow-up]. To
include size-balanced groups in the SVM models, we randomly selected 42
individuals from the original CAFEPS sample of 98 healthy controls. These
subjects were age- and sex-matched with the SSD and non-SSD groups
[mean age 15.21 ± 1.46 years (range 12–17 years), 69 % males], with
complete data available.
8/8/2014 e.Proofing
http://eproofing.springer.com/journals/printpage.php?token=me2DpncaDLIav2ZIXkLp6U4sZ0JnpjsMdeepZPkT_8U 9/32
For the development of the SVM classifiers, the sample from the original
dataset was divided into 2 sets: the training set [a randomly selected 80 % of
the sample (39 SSD, 26 non-SSD and 34 HC)] and the test set [the
remaining 20 % of the sample, with the same proportion of subjects
belonging to the SSD (N = 10), non-SSD (N = 6), and HC (N = 8) groups as
in the training set].
Variable preprocessing
Before dividing the original dataset into two sets, preprocessing required all
baseline variables defining each subject to be normalized and scaled to
achieve an equalized histogram. Qualitative variables were scaled as binary
matrices (e.g. for the sex variable, female [1,0], male [0,1]; for the family
history of psychosis (first degree relative) variable: presence [1,0], absence
[0,1]). Quantitative variables were scaled between 0 and 1 as follows: (1)
when the variable had a defined range (e.g. PANSS scale 30–210), it was
scaled as f(x) = (x − min(x ))/[max(x ) − min(x )], and (2) when there was no
defined range (e.g. weight), it was normalized as
f(x) = x − [mean(x ) − 5 × (standdev(x )]/[mean(x ) + 5 × (standdev(x )] − [mean(x
[ 31 ].
Variable selection and treatment of missing data
Table 1  summarizes the 1,050 baseline variables (747 clinical, 81
neuropsychological, 221 neuroimaging and 1 biochemical variable) included
in the dataset.
AQ2
Table 1
Baseline assessment variables included in the dataset
Clinical variables (n = 747)
 Demographic data
  Age, sex, ethnicity, socioeconomic status, parent and child years of
education
 Developmental, medical and psychiatric records
  Developmental history, educational history, personal medical and psychiatric
history, family psychiatric history, substance misuse, psychopharmacological
treatment, first psychotic symptoms, duration of illness
 Clinical and functional scales
i i i
i i i i
a
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  Lewis–Murray scale of obstetric data, FES, PAS-childhood subscale,
PANSS, HDRS, YMRS, SUMD—abbreviated version, CGI-S, CGAS, SCOS,
SDQ—parent and child version, WHO-DAS—short version
 Anthropometric data
  Weight, height, BMI
Neuropsychological variables (n = 81)
 Neuropsychological battery
  WISC-R/WAIS-III, TMT-A, TMT-B, Stroop test, TAVEC, FAS, COWAT,
WCST, NES
 Estimated IQ
–
 Cognitive domains
  Attention, speed of processing, learning and memory, working memory,
executive function, global cognition score
Neuroimaging variables(n = 221)
 ROIs
  Frontal lobe (whole frontal lobe, orbitofrontal cortex, dorsolateral
prefrontal cortex), parietal lobe, temporal lobe (whole temporal, mesial and
external subregions), occipital lobe, subcortical regions (caudate, putamen,
thalamus, internal capsule, globus pallidus), hippocampus
Biochemical variables (n = 1)
 Whole-brain GM, WM and CSF volumes, ICV
  TAS
BMI body mass index, CGAS children’s global assessment scale, CGI-S
clinical global impression scale—severity, COWAT control oral word
association test, CSF cerebrospinal fluid, FAS verbal fluency test, FES family
environment scale, GM gray matter, HDRS Hamilton depression rating scale,
ICV intracranial volume, IQ intelligence quotient, NES neurological
evaluation scale, PANSS positive and negative symptom scale, PAS premorbid
adjustment scale, SCOS Strauss–Carpenter outcomes scale, SDQ strengths
and difficulties questionnaire, SUMD scale to assess unawareness of mental
disorder, abbreviated version; TAS total antioxidant status, TAVEC Spanish
version of the California verbal learning test; TMT-A and TMT-B trail making
test, parts A and B, WAIS-III Wechsler adult intelligence scale, 3rd edition,
WCST Wisconsin card sorting test, WHO-DAS World Health Organization
disability assessment schedule, short version, WISC-R Wechsler intelligence
scale for children-revised, WM white matter, YMRS young mania rating scale
Ratings of every item, subscores (where appropriate) and total or summary
scores (where appropriate) were included. A complete description of the
clinical assessment procedure is provided as Online Resource 1
b
c
a
b
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For each test, raw scores and z scores of single test variables, raw and z
subscores (where appropriate) and raw and z total or summary scores (where
appropriate) were included. A complete description of the neuropsychological
assessment procedure is provided as Online Resource 1
For each ROI, raw volumes and volume percentages for each hemisphere and
for GM, WM and CSF (within each ROI) were obtained. A complete
description of the neuroimaging assessment procedure is provided as Online
Resource 1
Variables for which ≥15 % of the subjects had no information available were
excluded from the dataset. The following variables were therefore excluded:
birth weight and Apgar score, puberal status, the Strauss–Carpenter
outcomes scale (SCOS) (≥15 % of the subjects had no information available
for item number 6), the teacher version of the strengths and difficulties
questionnaire (SDQ), the parent–adolescent communication inventory
(PACI), the early adolescence, late adolescence, and adulthood subscales of
the Premorbid adjustment scale (PAS), duration of the disability in the
World Health Organization disability assessment schedule (WHO-DAS), raw
and z scores of the continuous performance test-II (CPT), cellular
glutathione peroxidase, catalase and superoxide dismutase activities, lipid
peroxidation and levels of glutathione in plasma.
Variables for which <15 % of the subjects had no information available were
included in the dataset. For these variables, missing values were treated as
follows. Zero imputation was performed for missing qualitative values
(missing values were expressed as empty matrices, [0, 0]). Subgroup mean
imputation was performed for missing quantitative values (by replacing the
missing value with the patient or control mean value for that variable,
depending on subject’s membership).
When a clinical variable was applicable only to patients [e.g. positive and
negative symptom scale (PANSS) or Hamilton depression rating scale
(HDRS)], values indicating the absence of symptoms or absence of
impairment were imputed to healthy controls (e.g. rating of 1 for PANSS
items, rating of 0 for HDRS items).
Statistics
Group differences at baseline
Group differences were tested for baseline demographic data (age, sex and
b
c
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ethnicity), duration of illness, antipsychotic treatment, total PANSS score
and children’s global assessment scale (CGAS) score. Binary comparisons
were performed for the following groups: (1) SSD vs. non-SSD, SSD vs.
controls and non-SSD vs. controls included in the original dataset, (2) SSD
vs. non-SSD, SSD vs. controls and non-SSD vs. controls included in the
training set, (3) SSD vs. non-SSD, SSD vs. controls and non-SSD vs.
controls included in the test set, (4) patients included in the training set vs.
patients included in the test set, (5) controls included in the training set vs.
controls included in the test set, (6) patients included and not included in the
dataset and (7) controls included and not included in the dataset.
For discrete categorical variables, Chi square or Fisher’s exact tests were
used. For quantitative variables, when they showed a normal distribution
(total PANSS score), Student’s t test was used; when they showed a non-
normal distribution (age, duration of illness and CGAS score), non-
parametric tests (Mann–Whitney U tests) were used. Differences of p < 0.05
were considered significant. All statistical tests were two-tailed and were
performed using SPSS for Windows, Version 18.0 [ 32 ].”
Development of the SVM classifiers
Several SVM models were developed. Within each model, the output
variable was membership in each stable K-SADS-based diagnostic group
(SSD vs. non-SSD, SSD vs. HC, and non-SSD vs. HC). For the purposes of
this study, we focused on the SSD vs. non-SSD model, as SSD and non-
SSD are clinically similar and unstable diagnostic groups during the FEP.
Thus, it makes sense to use this model to investigate the combination of
variables at an FEP that would help us to predict a stable diagnostic outcome
of SSD. As input variables, we entered a single vector with all the clinical,
neuropsychological and biological variables at baseline concatenated (the ‘All
variable’ classifier), or a single vector with the different set of variables
concatenated (the ‘clinical’, ‘neuropsychological’, ‘neuroimaging’ and
‘biochemical’ classifiers).
First, during a training phase, only the training set was used to compute each
SVM classifier. During this phase, the SVM learns from the training set and
finds a discriminating pattern from each diagnostic class (e.g. SSD vs. non-
SSD). To do this, the SVM draws an optimal separating hyperplane that
maximizes the separation between two groups. Such a hyperplane is based
on the subset of subjects lying closest to it and hence the most difficult to
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classify, namely, the support vectors [ 26 , 27 ]. To control possible
overfitting (i.e. the inability to generalize what has been learned to novel
data), several strategies were used. First, only linear kernels were used [ 25 ,
33 ]. Second, we performed a validation of the different classifiers using two
techniques in the training set: leave one out cross-validation (LOOCV) and
jackknifing. Both techniques estimate the ability of the classifier to reliably
classify new cases. LOOCV is an N-fold cross-validation method that
estimates the performance of a classifier by training the algorithm with N − 1
subjects and classifying the Nth subject repeatedly for all N subjects.
LOOCV is known to provide almost unbiased estimates with moderate
variance. Jackknifing repeats N  times the process of randomly
splitting N subjects into a test set with N/k subjects and a testing set with
(k − 1)N/k subjects. The estimation of the classifier performance is the
average of each repetition’s result. This enables a reduction of the variance
of the estimation. In this study N  = 1,000 and k = 5. The
performance of each classifier was estimated in terms of accuracy
(proportion of correct classifications), sensitivity (proportion of true positives
correctly identified) and specificity (proportion of true negatives correctly
identified).
After the training phase, the SVM classifiers were validated with the
previously unseen test dataset (formed by the remaining 20 % of the original
sample). The performance estimates (accuracy, sensitivity and specificity)
were again calculated.
Finally to rank all the variables by their predictive weight for a particular
diagnostic outcome and to improve the generalization ability of the classifier,
a feature selection phase was performed after the validation phase. The
feature selection phase enables the removal of irrelevant and redundant (e.g.
highly correlated) features in the dataset. By selecting those features which
discriminate best between groups, it increases the performance of the
predictive classifier. Feature selection is particularly helpful in small sample
classification problems, where the number of available training samples is
very small compared to the number of features, as was the case in our study.
Specifically enhanced recursive feature elimination (EnRFE), an RFE-
derived technique, was applied to each of our previously validated classifiers.
The basic principle of RFE is to rank and prune the available variables in the
classifier using the weight of each variable in constructing the SVM decision
hyperplane as a ranking criterion [ 34 ]. To do so, standard RFE removes a
jackknife
jackknife
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feature if it is weak or redundant at a particular step and retains independent
and relevant features. EnRFE is a RFE-derived technique which redefines
the criterion of removing features at each state of the training so that
redundant or weak features that improve performance estimates when
combined between them or with other relevant features can be retained
[ 35 ]. In an iterative scheme, the SVM-EnRFE classifier is trained until a
core set of variables with the highest discriminative power remains.
Performance estimates can be again calculated for these SVM-EnRFE
classifiers through validation procedures [ 34 ]. In our study En RFE was
performed for all the previously validated SVM classifiers, with the
exception of the ‘Biochemical variable’ classifier, where an EnRFE
technique could not be performed since there was only one input variable
(total antioxidant status—TAS, see Table 1 ). All SVM-EnRFE classifiers
were validated using LOOCV, jackknifing and the test dataset and
performance estimates were calculated for each of them. Also to assess the
statistical significance of the different estimates, permutation testing was
performed for each of the SVM and SVM-EnRFE classifiers validated with
LOOCV and jackknifing [ 36 ]. Although the development of a single SVM
classifier does not require any correction for multiple comparisons, given that
multiple SVMs were generated in our study (n = 45), critical p values were
corrected for multiple comparisons using false discovery rate (FDR) type II
(q = 0.5) [ 37 ]. All analyses were performed using MATLAB Version
7.13.0.564 (R2011b) and the Statistic Toolbox Version 7.6 (R2011b) [ 38 ].
Results
Sample description at baseline
Patients included in the dataset (n = 81) and patients excluded from the
dataset (n = 29) did not differ significantly in age, sex, ethnicity, total
PANSS score, CGI-S score, or CGAS score at baseline. The same was true
for the healthy controls included in the dataset (n = 42) and excluded from
the dataset (n = 56) (data available upon request).
Table 2  shows the demographic and clinical characteristics at baseline of the
81 (49 SSD, 32 non-SSD) patients and 42 healthy controls who were
included in the dataset and who were assigned either to the training set or to
the test set before the development of the SVM classifiers. SSD and non-
SSD, SSD and controls, and non-SSD and controls included in the original,
training or test datasets did not differ significantly in demographic or clinical
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characteristics (except for a higher CGAS score at baseline in the control
groups compared with both patient groups). Neither did patients and controls
included in the training set nor patients and controls included in the test set.
Table 2
Baseline demographic and clinical characteristics of SSD patients, non-SSD patients and controls within the training and the test dataset
 
Whole dataset (N = 123) p values Training set (
SSD
(N = 49)
Non-SSD
(N = 32)
HC
(N = 42)
SSD
vs.
non-
SSD
SSD
vs. HC
Non-
SSD
vs. HC
SSD
(N
Age (years),
mean (SD)
[range]
15.2 (1.9)
[9–17]
15.6 (1.8)
[11–17]
15.2 (1.5)
[12–17] 0.36 0.46 0.09
15.2 (2.1)
[9–17]
Male sex, N
(%) 38 (77.6) 19 (59.4) 29 (69.0) 0.08 0.36 0.39 31 (79.5)
Ethnicity
(Caucasian),
N (%)
43 (87.8) 29 (90.6) 40 (95.2) 0.99 0.28 0.65 34 (87.2)
PANSS total
score, mean
(SD)
89.4 (17.8) 90.4(24.1) – 0.83 – – 89.1 (18.6)
CGAS score,
mean (SD) 33.5 (14.7)
34.7
(14.9) 91.9 (4.5) 0.56 <0.001 <0.001 32.3 (13.2)
Duration of
illness
(days), mean
(SD), [range]
70.9 (52.6)
[2–180]
54.7
(47.0) [5–
180]
– 0.20 – – 72.1 (53.6)[2–180]
Antipsychotic
treatment, N
(%)
47 (95.9) 32 (100) – 0.52 – – 37 (94.9)
Subjects per
site, N Site
1/2/3/4/5
25/8/0/3/13 16/4/5/2/5 27/1/3/3/8 0.06 0.06 0.32 19/6/0/3/11
In all cells, % refers to percentages (within columns) of participants. For qualitative variable comparisons, Chi square test (
showed a normal distribution (total PANSS score), Student’s t test was used; when they showed a non-normal distribution (age, duration of illness and CGAS score), non-parametric tests (Mann–Whitney 
Statistically significant p values in bold
CGAS children’s global assessment scale, PANSS positive and negative symptom scale
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Table 3  shows the performance estimates of the SVM-EnRFE classifiers
(SSD vs. non-SSD, SSD vs. HC and non-SSD vs. HC classifiers),
considering all variables together or the different sets of variables, and
validated with LOOCV, with jackknifing or with the test set. Among the SSD
vs. non-SSD models, the highest performance estimates were obtained with
the ‘All variable’ classifier validated with the test set (Table 3 ).
Table 3
Performance estimates of the SVM-En RFE classifiers after validation with LOOCV, with jackknifing and with the
test dataset
Baseline
variables
SSD vs. non-SSD (N = 49 vs.
32)
SSD vs. HC (N = 49 vs. 42)
Non-SSD vs. HC (
42)
acc sens spec acc sens spec acc
All variables (n = 1,050)
 LOOCV 0.78** 0.87** 0.65** 0.99*** 0.99*** 0.99*** 0.99***
 Jackknifing 0.79*** 0.87*** 0.68*** 0.99*** 0.99*** 0.99*** 0.99***
 Test set 0.81 0.90 0.67 0.99 0.99 0.99 0.99
Clinical variables (n = 747)
 LOOCV 0.91*** 0.87*** 0.96*** 0.99*** 0.99*** 0.99*** 0.99***
 Jackknifing 0.86** 0.88* 0.83** 0.99** 0.99** 0.99** 0.99**
 Test set 0.75 0.90 0.50 0.99 0.99 0.99 0.93
Neuropsychological variables (n = 81)
 LOOCV 0.63 0.74 0.46 0.67*** 0.62*** 0.74*** 0.58***
 Jackknifing 0.63 0.66 0.57 0.87** 0.85** 0.88** 0.84**
 Test set 0.56 0.70 0.33 0.83 0.80 0.88 0.67
Neuroimaging variables (n = 221)
 LOOCV 0.60 0.67** 0.50 0.88** 0.87 0.88*** 0.87
 Jackknifing 0.60 0.67* 0.50 0.67** 0.65* 0.69*** 0.59
 Test set 0.50 0.40 0.67 0.61 0.40 0.88 0.61
Biochemical variables (n = 1)
 LOOCV 0.45 0.54 0.31 0.63* 0.74* 0.5 0.63*
 Jackknifing 0.46 0.56 0.31 0.63* 0.74** 0.5 0.63*
a
ns ns ns
ns ns ns
ns ns ns
ns ns
a
ns ns ns ns
ns ns ns ns
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 Test set 0.63 0.60 0.67 0.78 0.80 0.75 0.64
SVM Input: baseline variables. SVM Output: diagnostic outcome (SSD vs. non-SSD, SSD vs. HC, and non-SSD
vs. HC).acc accuracy, EnRFE enhanced-recursive feature elimination, HC healthy controls, 
out cross-validation, non-SSD non-schizophrenia spectrum disorders, sens sensitivity, 
schizophrenia spectrum disorders, SVM support vector machine
EnRFE was not performed for the ‘Biochemical variable’ classifier since the number of input variables was
n = 1
* p < 0.05, ** p < 0.01, *** p < 0.001, ns non-significant. For all the LOOCV- and jackknifing-validated
classifiers, critical p values are corrected for multiple comparisons with false discovery rate (FDR) type II
(q = 0.5)
For the ‘All-variable-SSD vs. non SSD’ classifier, after EnRFE and
validation with the test set, 243 variables (213 clinical and 30 neurocognitive
variables) were selected because of their highest discriminative value for a
diagnostic outcome of SSD. Table 4  shows the main first-ranked variables
within this SVM-EnRFE model. Biochemical and neuroimaging variables
were all ruled out by EnRFE, as they did not provide any additional
predictive value within the best SSD model. The combination of 243 clinical
and cognitive variables at baseline made it possible to classify patients into
those who will eventually be diagnosed with SSD with an accuracy of 0.81,
a sensitivity of 0.90, and a specificity of 0.67.
Table 4
Main baseline variables with the highest predictive weight for a diagnostic
outcome of SSD
Clinical variables (n = 213)
 >Severity of negative or disorganized symptoms preceding and/or during
FEP: flattened affect, social withdrawal, stereotyped thinking and conceptual
disorganization (medical records and items P2, N1, N4, N7 of the PANSS)
 >Severity of hallucinations (item P3 of the PANSS)
 <Insight (item G12 of the PANSS)
 <Severity of affective symptoms (YMRS and HDRS total scores)
 >Prescription of risperidone and aripiprazole
 >Antipsychotic dose
 >% of ‘true’ responses within particular FES items (e.g. item 20, 22)
a
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 <Severity of somatic complaints (items G1 of the PANSS and 13 of the
HDRS) or hypochondria (item 15 of the HDRS)
 >Prevalence of obstetric complications (Lewis–Murray scale of obstetric
data)
Neuropsychological variables (n = 30)
 <Estimated IQ
 <Attention score
 <Global cognition score
 >Motor coordination impairment (NES motor coordination score)
Neuroimaging variables (n = 0)
 None
Biochemical variables (n = 0)
 None
Main first-ranked variables within the SVM-EnRFE ‘SSD vs. non-SSD’
classifier after validation with the test dataset
EnRFE enhanced recursive feature elimination, FEP first episode of
psychosis, FES family environment scale, HDRS Hamilton depression rating
scale, IQ intelligence quotient, NES neurological examination scale, PANSS
positive and negative symptom scale (P positive symptom subscale, N
negative symptom subscale, G general symptom Subscale), SSD schizophrenia
spectrum disorder, SVM support vector machine, YMRS young mania rating
scale
Discussion
In the present study, we found that SVMs could be helpful multivariate
statistical tools in the search for predictors of diagnostic outcomes in patients
with early-onset FEP. By grouping together a large amount of clinical,
neuropsychological and biological data at baseline (during the FEP), we
designed an SVM model that selected a combination of clinical variables
(higher severity of negative symptoms and hallucinations or poorer insight)
and neuropsychological variables (higher impairment in attention, global
cognition, and motor coordination) as those with the highest predictive value
for a diagnostic outcome of SSD. This combination of variables classified
child and adolescent FEP patients who would eventually be diagnosed with
SSD with an accuracy of 0.81. Total antioxidant status or neuroimaging
variables such as frontal gray volume were not selected for the best SVM
model as they did not provide additional predictive value. Therefore, the
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assessment of particular clinical and neuropsychological variables can be
helpful for guiding differential diagnosis during an early-onset FEP.
To our knowledge, this is the first study to use an SVM model as a
multivariate statistical tool to identify particular variables from different
sources that might predict a diagnostic outcome of SSD in the early stages of
an early-onset FEP. Despite the increasing application of SVMs in medicine
as tools for predicting diagnosis at early stages of disease [ 39 – 41 ], their
application in psychosis has been limited (Orru, Petterson-Yeo et al. [ 42 ] for
a review). SVMs have been used more as tools to investigate potential
biomarkers for a specific diagnosis in cross-sectional studies that only
included chronic, well-characterized patients. In addition, they have usually
used a single source of data (mainly neuroimaging data) [ 19 , 43 – 45 ]. SVMs
have also been used to search for predictors of disease course in patients
with FEP [ 46 ] and of transition to psychosis in at-risk individuals [ 47 – 49 ].
However, no studies had previously used SVMs to search for predictors of
diagnostic outcome in early-onset FEP.
In our study, the selected predictive variables for a diagnostic outcome of
SSD are to some extent consistent with those described in previous
longitudinal studies in FEP patients using traditional multivariate approaches.
With regard to clinical variables, history of obstetric complications [ 12 ], the
presence of negative symptoms [ 9 , 13 ] and poor insight [ 50 ] have been
described as good predictors of diagnosis outcome or diagnostic shift to
schizophrenia both in adult and adolescent samples. Furthermore positive
symptoms such as hallucinations are usually more frequent and severe in
SSD patients than in patients with other psychotic disorders [ 51 ]. Lower
severity of depressive symptoms also predicted a diagnostic outcome of SSD
in our sample, as it predicted change of diagnosis to SSD in a previous study
by our group which used a clinically comparable sample of FEP patients
from the CAFEPS study [ 52 ]. Although other previous longitudinal studies
in FEP patients using traditional multivariate approaches have reported an
association between lifetime substance disorder and change of diagnosis to
SSD [ 9 ], substance use or presence of substance disorder were not selected
in the best SSD vs. non-SSD predictive model, which was also congruent
with a previous CAFEPS-related study [ 8 ]. Conversely with regard to family
communication and environment, our study found that specific items from
the family environment scale (FES) (e.g. higher percentage of ‘true’ answers
for item 20: having few rules at home or item 22: struggling with venting at
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home) were associated with a diagnostic outcome of SSD, whereas a
previous study by our group did not find an association between family
communication skills (assessed using the Parent-Adolescent Communication
Inventory—PACI) and 1-year diagnosis of schizophrenia or bipolar disorder
[ 53 ]. Furthermore, we found that being prescribed risperidone or
aripiprazole at baseline was a good predictor of SSD diagnostic outcome, in
combination with a higher severity of negative symptoms and the rest of the
selected clinical and cognitive variables, whereas another CAFEPS-derived
study found that clinicians seem to prescribe olanzapine and quetiapine more
than risperidone when negative symptoms are prominent [ 54 ]. However, the
above-mentioned studies (including previous CAFEPS-related studies) used
traditional multivariate statistical approaches (e.g. logistic regression) and
focused only on a specific source of measurements (i.e. clinical) and a
limited number of variables (e.g. total scores or subscores of a specific
scale), whereas our study relied on the simultaneous assessment of clinical,
cognitive, biochemical and neuroimaging measurements at a single-patient
level instead of at a group level at a very early stage of the illness. Our
findings reinforce the idea that clinical prediction in psychiatry requires a
combination of multiple measurements from different sources, especially in
complex disorders [ 24 ].
A generalized deficit in the cognitive domain and the presence of
neurological soft signs have been described in schizophrenia and other
psychotic disorders such as affective psychoses [ 55 – 59 ], thus potentially
explaining the low performance estimates of the EnRFE ‘SSD vs. non SSD’
models that included only neuropsychological variables (and the non-
significance for those validated with LOOCV and jackknifing). However,
within the model that used all baseline variables together, the combination of
these and other neuropsychological variables with particular clinical variables
easily predicted a diagnostic outcome of SSD. Again, this finding supports
the need for combining multiple inputs from clinical and neuropsychological
sources when predicting a diagnosis of psychosis. It is also consistent with
findings from studies reporting that cognitive impairment is more severe,
appears earlier, and tends to be more independent of clinical symptoms in
schizophrenia than in other psychotic disorders, especially at onset [ 15 , 60 ].
Contrary to our expectations [ 15 , 16 ], executive function impairment was
not selected among the variables with the highest predictive weight for a
diagnostic outcome of SSD.
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Performance estimates of the EnRFE ‘SSD vs. non-SSD’ model which
included only neuroimaging variables were relatively low (and non-significant
for those validated with LOOCV and jackknifing). Furthermore, within the
EnRFE classifier that considered all the baseline variables together,
neuroimaging variables were not selected since they did not provide any
additional predictive value for the diagnostic outcome of SSD. These results
were not congruent with those from previous studies including individual
neuroimaging data for diagnostic prediction of SSD and other psychotic
disorders [ 19 , 45 ]. GM deficits in prefrontal cortex, insula, amygdala or
hippocampus have been described as accurate predictors of an SSD
diagnosis both in first episode and chronic patients [ 18 – 20 ], and higher
estimates (e.g. accuracies >0.75) for neuroimaging variables alone have been
reported. However, since these studies are cross-sectional and based on
samples of adult patients, their results are not comparable with ours.
Moreover, studies in child and adolescent psychiatric disorders using
neuroimaging data and SVMs for the prediction of diagnostic outcomes
usually report lower performance estimates than studies in adult samples
[ 25 ]. In addition, since only volumetric measures for various regions of
interest (ROIs) were included in our model, our findings are debatable,
considering that the structural abnormalities that have been described in
brains of patients with SSD and other psychotic disorders are subtle and
actually very distributed (Yu, Cheung et al. [ 18 ] for a meta-analysis). Lastly
this multicenter study had several limitations in terms of acquisition and
processing procedures (see Online Resource 1 for a detailed description of
the neuroimaging procedure). All this may have precluded finding
neuroimaging predictors of diagnostic outcome [ 25 ].
Furthermore within the classifier that used all the baseline variables together,
total antioxidant status (TAS) (the only biochemical variable) did not provide
additional predictive value for a diagnostic outcome of SSD. Also
performance estimates of the ‘SSD vs. non-SSD’ models which included
only this biochemical variable were relatively low (and non-significant for
those validated with LOOCV and jackknifing). These results are in line with
those from previous studies in FEP patients where biochemical markers such
as decreased TAS seem to be more associated with severity and chronicity
of psychosis than with a specific diagnosis [ 21 ]. This may also be due to the
fact that the other sets of variables outnumbered the biochemical set. Finally
we were not able to study the predictive value of other biochemical variables
such as cellular enzyme activities, lipid peroxidation or glutathione levels,
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since they were excluded following our missing data strategy.
The findings from this study should be interpreted in the context of other
important limitations. First, most of the patients included had acute first
episodes of psychosis while hospitalized, thus precluding generalization of
the findings. Second, during construction of the dataset, several subjects
were excluded (e.g. those who had not undergone neuroimaging);
consequently, the results could be biased, since these patients could be the
most acutely or severely ill and least cooperative patients. That said, patients
included in the analysis did not differ significantly from those excluded in
terms of demographic data, severity of symptoms or functional impairment.
Third, several variables were discarded and zero and mean imputation were
performed for treating missing data. This may have affected the performance
of the classifier and the generalizability of the results. Fourth, only 20 % of
the sample that came from the same dataset as the training set was used for
the testing phase. Fifth, there was a small imbalance in the sample size of the
SSD (N = 49), non-SSD (N = 32) and HC (N = 42) group. This may have
artificially increased the accuracy of the SSD vs. non-SSD classifier, since it
was biased toward the sensitivity estimate (Table 3 ). Sixth, the use of a
larger sample size and a higher number or a different set of neuroimaging
and biochemical variables could have increased classification accuracy and
could have revealed biomarkers with higher predictive value for a diagnostic
outcome of SSD. Seventh, a longer follow-up period could have enabled us
to rely on more accurate gold-standard diagnostic outputs for developing the
classifier, since there was a possibility that the diagnoses changed again after
the 2-year observation period [ 61 , 62 ]. The stability of schizophrenia is
very high even in follow-up studies as long as 11 years (80 %) [ 61 ] or even
42 years (91 %) [ 62 ], but it is possible that the continuity with adult
schizophrenia is not total. There may be cases where this change in diagnosis
is not related to low accuracy of previous diagnosis but to “true changes”.
An approach of considering schizophrenia as one clinical manifestation of
long-life developmental abnormalities, with other possible clinical
manifestations at other times, may also be a valid one. Last, since we
included all available baseline clinical, neuropsychological, magnetic
resonance imaging brain volumetric and biochemical variables in a
multivariate high-dimensional model, one could argue that the study was not
hypothesis-driven but exploratory. Although they might lack statistical rigor,
exploratory analyses make it possible to find patterns in the data. These
patterns can then be statistically tested (1) by permutation analyses, which
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provide a significance value for each of the classification and (2) by dividing
the original dataset into the training dataset and the previously unseen test
dataset, as we did in this study.
Finally, since the clinical variables that conformed to the DSM diagnosis
were included in the classifier, and since they outnumbered the other types
of variables, the performance of the classifier might be expected to be
excellent, with clinical variables being obviously the most predictive.
Moreover, since the clinician is able to diagnose with 80 % accuracy at
baseline (as around 20 % of diagnoses is unstable at this stage) and the SVM
model did this with the same accuracy (81 %), one might wonder what SVM
adds to assist differential diagnosis. The answer may be that it can be helpful
as a statistical multivariate predictive tool in the search for sensitive and
specific predictors of diagnosis rather than as a classification tool, which was
the main aim of this study. Description of these predictors could then assist
clinicians in terms of differential diagnosis at the FEP.
The main strengths of our study include the recruitment of child and
adolescent patients at first onset, which avoids the potential confounding
effect of medication and other factors related to disease progression; the
relatively large sample size, the use of a ‘previously unseen’ test dataset, the
wealth of data and the number of different predictors. Moreover compared
with other multivariate analysis methods, SVMs offer several advantages,
since they enable the assessment of high-dimensional datasets including
linearly and non-linearly highly correlated variables, and the selection of a
combination of variables (even if redundant or with a weak predictive weight
when separately considered) that may provide the best class separation
between two groups, with no need for multiple comparison correction, with
minimisation of the problem of circularity and with reduction of the
generalization error, especially after using EnRFE. This in turn may help
devise more parsimonious clinical and neuropsychological batteries to assess
patients at intake, when patients are clinically similar and their diagnoses are
unstable, and thus help clinical decision making at this stage.
In summary, using SVMs, we found that a combination of clinical variables
(severity of negative symptoms, hallucinations or poor insight) and
neuropsychological variables (attention, global cognitive or motor
coordination deficits) at the emergence of an early-onset FEP had the highest
predictive value for a diagnostic outcome of SSD, as opposed to
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neuroimaging and biochemical variables which did not provide additional
predictive value. Hence, clinical judgment based on comprehensive clinical
and cognitive assessment still seems to be the most valuable tool for guiding
differential diagnosis in patients with early-onset FEP. Furthermore, current
psychosis classification systems should continue to be based on traditional
nosology until strong neurobiological evidence can support change through
sensitive and specific biomarkers [ 63 ]. To find this evidence, SVMs could
prove to be promising tools.
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